Literature DB >> 3257496

Low-dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat.

C H Polman1, I Matthaei, C J de Groot, J C Koetsier, T Sminia, C D Dijkstra.   

Abstract

Experimental allergic encephalomyelitis (EAE) in Lewis rats is an acute monophasic autoimmune disease. It can be treated prophylactically and therapeutically with high doses of cyclosporin A (CsA). Here we demonstrate that low-dose CsA does not prevent a first attack of EAE, but, on the contrary, induces a chronic relapsing form of the disease in 100% of Lewis rats examined. Possible explanations for the high relapse rate after low-dose CsA treatment are discussed. Further studies will be needed to evaluate the immunological mechanisms responsible for these results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257496     DOI: 10.1016/0165-5728(88)90069-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  Chronic remitting experimental allergic encephalomyelitis in Lewis rats as a model of multiple sclerosis.

Authors:  E Zapryanova; D Deleva; M Bakalska; N Filchev
Journal:  Neurosci Behav Physiol       Date:  1999 Jan-Feb

2.  Ganglioside spinal cord changes in chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rats.

Authors:  E Zaprianova; D Deleva; B Hauttecoeur; M Bakalska; A Filchev
Journal:  Neurochem Res       Date:  1997-02       Impact factor: 3.996

3.  Interleukin-12 induces relapse in experimental allergic encephalomyelitis in the Lewis rat.

Authors:  T Smith; A K Hewson; C I Kingsley; J P Leonard; M L Cuzner
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

4.  The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A.

Authors:  M P Pender; G P Stanley; G Yoong; K B Nguyen
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

5.  The role of serum factors in the suppression of experimental allergic encephalomyelitis: evidence for immunoregulation by antibody to the encephalitogenic peptide.

Authors:  I A MacPhee; M J Day; D W Mason
Journal:  Immunology       Date:  1990-08       Impact factor: 7.397

6.  Regulation of resistance against adjuvant arthritis in the Fisher rat.

Authors:  A G van de Langerijt; P L van Lent; A R Hermus; L B van de Putte; W B van den Berg
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

Review 7.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 8.  Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale.

Authors:  Dimitrios Karussis; Panayiota Petrou
Journal:  Immunol Res       Date:  2018-12       Impact factor: 2.829

9.  Ganglioside changes in brain in chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat.

Authors:  E Zaprianova; D Deleva; A Filchev
Journal:  Neurochem Res       Date:  1998-11       Impact factor: 3.996

10.  Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats.

Authors:  I Huitinga; S R Ruuls; S Jung; N Van Rooijen; H P Hartung; C D Dijkstra
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.